ImmunityBio, Inc. (IBRX) — Executive Compensation
Fiscal year ended December 2025
This page summarizes ImmunityBio, Inc. (IBRX) named executive officer compensation from the most recent SEC DEF 14A proxy statement. Richard Adcock (CEO) received $12,716,953 in reported total compensation@if($peoPaid !== null), with $6,222,909 "actually paid" under the SEC pay-versus-performance rule. @endif Total shareholder return for the period was 14.85.
Other named executives — average
- Average reported total
- $5,761,037
- Average actually paid
- $2,920,536
Frequently asked questions
- Who is the CEO of IBRX and how much are they paid?
- Richard Adcock serves as CEO of ImmunityBio, Inc.. For fiscal year ending December 2025, reported total compensation was $12,716,953.
- What is included in executive compensation?
- SEC Summary Compensation Table figures include base salary, cash bonuses, stock awards (grant-date fair value), option awards, non-equity incentive plan compensation, pension value changes, and all other compensation. "Actually Paid" compensation follows the newer SEC pay-versus-performance rule and reflects realized value.
- What is pay-versus-performance?
- The SEC pay-versus-performance disclosure requires companies to show the relationship between executive pay "actually paid" and total shareholder return (TSR) over recent fiscal years, so investors can evaluate pay alignment.